|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.01.26 - 18:42
|
Börsenradio Schlussbericht, Di., 13.01.2026: Rekord-DAX, Rekord-Gold, Jahresstart-Rally läuft, Berichtssaison macht Druck (BRN)
|
|
|
Der Optimismus bleibt hoch: Der DAX markierte ein weiteres Allzeithoch bei 25.508 Punkten und schloss bei 25.421 Punkten mit +0,1%. Der EuroStoxx50 legte um +0,2% auf 6.029 Stellen zu. Im DAX stach Symrise mit +5,1% heraus, nach einem angekündigten Aktienrückkauf von bis zu 400 Mio. EURO. Treiber war auch Zalando, die Aktie gewann zeitweise über 6% nach einer Hochstufung durch Barclays. Verbio sprang um +14% auf über 24 EURO. In den USA startete die Berichtssaison, im Fokus stehen die Großbanken. JPMorgan meldete 13 Mrd. USD Gewinn nach 14 Mrd. USD, belastet durch 2,2 Mrd. USD Rückstellungen im Zuge des Apple-Kreditkartendeals. BASF übernimmt AgBiTech, Qualcomm vereinbarte eine Milliarden-Kooperation mit VW, Diageo prüft Optionen für China-Assets. Vattenfall erhielt grünes Licht für den Offshore-Windpark Nordlicht mit über 1,6 GW. Gold markierte ebenfalls Rekordwerte bei 4.620 USD....
|
|
|
13.01.26 - 18:33
|
AM Best Assigns Preliminary Credit Assessment to Beazley Bermuda Insurance Limited (Business Wire)
|
|
|
LONDON--(BUSINESS WIRE)--#insurance--AM Best has assigned a Preliminary Credit Assessment (PCA) to Beazley Bermuda Insurance Limited (BBIL) (Bermuda) with a Financial Strength Assessment of A pca (Excellent) and a Long-Term Issuer Credit Assessment of “a+” pca (Excellent). The outlook assigned to the PCA is stable.
The PCA reflects BBIL's balance sheet strength, which AM Best assesses as very strong, as well as its adequate operating performance, neutral business profile and appropriate enterprise risk management. The PCA also factors in lift from BBIL's ultimate parent, Beazley plc, reflecting the strategic importance of BBIL to the group.
BBIL's balance sheet strength is underpinned by its risk-adjusted capitalisation, which is expected to be at the strongest level, as measured by Best's Capital Adequacy Ratio (BCAR), as well as the understanding that BBIL will follow Beazley plc's prudent reserving and investment strategy. BBIL's risk-adjusted capitalisation will be supported by a large capit...
|
|
|
13.01.26 - 18:33
|
Saba Capital Releases Letter Sent to Workspace Group Plc′s Board of Directors (Business Wire)
|
|
|
Proposes a Managed Wind-Down of the Company, Which Should Include an Orderly Strategic Sale of Assets, Systematic Repayment of Debt and the Timely Return of Capital to ShareholdersLONDON--(BUSINESS WIRE)--Saba Capital Management, L.P. (together with certain of its affiliates, “Saba” or “we”), which owns approximately 13.5% of the outstanding share capital of Workspace Group plc (WKP:LSE) (the “Company”), today disclosed that it sent a letter to the Company's Board of Directors (the “Board”) on 8 January 2026. In the letter, Saba urged the Board to recommend the Company proceed with a managed wind-down, which should include an orderly strategic sale of its assets, systematic repayment of debt and the timely return of capital to shareholders.
A copy of Saba's letter can be found here.
***
About Saba
Saba Capital Management, L.P. is a global alternative asset management firm that seeks to deliver superior risk-adjusted returns for a diverse group of clients. Founded in 2009 by Boaz Weinstei...
|
|
|
|
|
|
|
|
|
|
|
13.01.26 - 18:18
|
Holding(s) in Company (GlobeNewswire EN)
|
|
|
Endeavour Mining plc (“the Company”) announces that it received the following notification from BlackRock Inc. of its interests in the Company as at 13 January 2026...
|
|
|
|
|
|
|
13.01.26 - 18:03
|
Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--#AstraZeneca--Modella AI, a leader in artificial intelligence for life sciences, today announced that it has been acquired by AstraZeneca, expanding the companies' existing collaboration to advance the application of multi-modal AI foundation models and AI agents across AstraZeneca's global oncology portfolio.
The acquisition follows a multi-year agreement with AstraZeneca announced in July 2025 and will integrate Modella AI's generative and agentic AI platform into AstraZeneca's oncology research and development organization, supporting efforts to accelerate clinical development, enhance biomarker discovery, and enable the next wave of data-driven decision-making across the pipeline.
“Oncology drug development is becoming more complex, more data-rich, and more time-sensitive, and our companies expect AI solutions that are not only powerful but truly deployable in global trials and clinical settings,” said Gabi Raia, Chief Commercial Officer of Modella AI. “By joining As...
|
|
|
|
|
|
Alle News zu Großbritannien 10149.0045 +0.02% (FTSE 100 Kurs)
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
